DelveInsight’s, “Oncolytic Virus Cancer Therapy Pipeline Insight 2024” report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report

• DelveInsight’s Oncolytic Virus Cancer Therapy pipeline report depicts a robust space with 120+ active players working to develop 125+ pipeline therapies for Oncolytic Virus Cancer Therapy treatment.
• The leading Oncolytic Virus Cancer Therapy Companies working in the market include Genelux Corporation, Candel Therapeutics, CG Oncology, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Turnstone Biologics, and others.
• Promising Oncolytic Virus Cancer Therapy in the various stages of development include ONCOS-102, gemcitabine, VRT106, CG0070, Keytruda,  pembrolizumab, TILT-123, and others.
• April 2024:- Guangzhou Virotech Pharmaceutical Co., Ltd.- A Phase I Clinical Study to Evaluate the Safety, Tolerability, Biodistribution Characteristics, Biological Effects and Initial Efficacy of Recombinant Oncolytic Virus M1 for Injection (VRT106) in the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors.
• April 2024:- Mridula George, MD- This is a phase 2 study to evaluate the safety and efficacy of the combination of INCMGA00012 and pelareorep and to see how well they work in treating patients with triple negative breast cancer that has spread to other parts of the body (metastatic).

 

Request a sample and discover the recent advances in Oncolytic Virus Cancer Therapy treatment drugs @ Oncolytic Virus Cancer Therapy Pipeline Outlook Report

 

Oncolytic Virus Cancer Therapy Overview

Oncolytic virotherapy is a treatment of using a virus that can replicate itself to kill cancer cells. There are many species of viruses, but not all of them can be designed to be an oncolytic virus (OV). The typical features of these OVs must include being non-pathogenic, the ability to target and kill the cancer cells, and the capacity of being transformed to express tumor-killing factors through genetic engineering methods. Tumor selectivity could be concerned with the level of receptor-mediated cell entry, intracellular antiviral responses, or restriction factors that determine the susceptibility of the infected cell that leads to viral gene expression and replication.

 

Oncolytic Virus Cancer Therapy Emerging Drugs Profile

• Olvi-Vec: Genelux Corporation
• CAN-2409: Candel Therapeutics
• CG0070: CG Oncology
• Pelareorep: Oncolytics Biotech
• ParvOryx: Oryx GmbH
• SND005: Jiangsu Sinorda Biomedicine
• VCN-01: VCN Biosciences

 

Find out more about Oncolytic Virus Cancer Therapy treatment drugs @ Drugs for Oncolytic Virus Cancer Therapy Treatment

 

Oncolytic Virus Cancer Therapy Therapeutics Assessment

There are approx. 120+ key Oncolytic Virus Cancer Therapy companies which are developing the therapies for Oncolytic Virus Cancer Therapy. The Oncolytic Virus Cancer Therapy companies which have their Oncolytic Virus Cancer Therapy drug candidates in the most advanced stage, i.e. phase III include, Genelux Corporation.

 

DelveInsight’s Oncolytic Virus Cancer Therapy report covers around 125+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Learn more about the emerging Oncolytic Virus Cancer Therapy pipeline therapies @ Oncolytic Virus Cancer Therapy Clinical Trials

 

Oncolytic Virus Cancer Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular

 

Oncolytic Virus Cancer Therapy Products have been categorized under various Molecule types such as

• Oncolytic Viruse

 

Oncolytic Virus Cancer Therapy Companies

Genelux Corporation, Candel Therapeutics, CG Oncology, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Turnstone Biologics, and others.

 

Dive deep into rich insights for new drugs for Oncolytic Virus Cancer Therapy Treatment, visit @ Oncolytic Virus Cancer Therapy Drugs

 

Scope of the Oncolytic Virus Cancer Therapy Pipeline Report

• Coverage- Global
• Oncolytic Virus Cancer Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Oncolytic Virus Cancer Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Oncolytic Virus Cancer Therapy Companies- Genelux Corporation, Candel Therapeutics, CG Oncology, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Turnstone Biologics, and others.
• Oncolytic Virus Cancer Therapy Therapies- ONCOS-102, gemcitabine, VRT106, CG0070, Keytruda,  pembrolizumab, TILT-123, and others

 

For further information on the Oncolytic Virus Cancer Therapy Pipeline Therapeutics, reach out @ Oncolytic Virus Cancer Therapy Treatment Drugs

 

Table of Content

1. Introduction
2. Executive Summary
3. Oncolytic Virus Cancer Therapy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Oncolytic Virus Cancer Therapy– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Olvi-Vec: Genelux Corporation
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. SND005: Jiangsu Sinorda Biomedicine
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. AloCelyvir: Orgenesis
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. VCN-01: VCN Biosciences
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. SynOV 1.3: Beijing Syngentech
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Oncolytic Virus Cancer Therapy Key Companies
24. Oncolytic Virus Cancer Therapy Key Products
25. Oncolytic Virus Cancer Therapy- Unmet Needs
26. Oncolytic Virus Cancer Therapy- Market Drivers and Barriers
27. Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion
28. Oncolytic Virus Cancer Therapy Analyst Views
29. Oncolytic Virus Cancer Therapy Key Companies
30. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/